STOCK TITAN

Achieve Life Sciences Inc. - ACHV STOCK NEWS

Welcome to our dedicated news page for Achieve Life Sciences (Ticker: ACHV), a resource for investors and traders seeking the latest updates and insights on Achieve Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Achieve Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Achieve Life Sciences's position in the market.

Rhea-AI Summary
Achieve Life Sciences CEO to participate in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
earnings
-
Rhea-AI Summary
Achieve Life Sciences, Inc. (NASDAQ: ACHV) will report its second quarter 2023 financial results on August 14, 2023. The company will host a conference call and webcast on August 15, 2023, at 8:30 AM EDT. Webcast replay will be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
conferences
Rhea-AI Summary
Achieve Life Sciences announces a registered direct offering of 3,000,000 shares of common stock at $5.50 per share, expecting to raise approximately $16.5 million. The proceeds will be used for product development, regulatory activities, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.15%
Tags
offering
-
Rhea-AI Summary
Achieve Life Sciences announces positive topline results from Phase 3 ORCA-3 trial of cytisinicline for smoking cessation, showing statistically significant benefit compared to placebo. Cytisinicline demonstrated a 6x increase in odds of continuous smoking abstinence at 6 months. Treatment well tolerated with low rates of adverse events. Conference call scheduled for May 23.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.8%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.71%
Tags
earnings
Achieve Life Sciences Inc.

Nasdaq:ACHV

ACHV Rankings

ACHV Stock Data

154.82M
19.40M
9.28%
25.9%
3.04%
In-Vitro Diagnostic Substance Manufacturing
Manufacturing
Link
US
Seattle

About ACHV

achieve life sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.